Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

来那度胺 Carfilzomib公司 多发性骨髓瘤 地塞米松 医学 肿瘤科 移植 内科学
作者
Elizabeth O’Donnell,Clifton C. Mo,Andrew J. Yee,Omar Nadeem,Jacob P. Laubach,Jacalyn Rosenblatt,Nikhil C. Munshi,Shonali Midha,Diana Cirstea,Pavlina Chrysafi,Nora Horick,Paul G. Richardson,Noopur Raje
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:11 (6): e415-e424 被引量:6
标识
DOI:10.1016/s2352-3026(24)00070-x
摘要

Summary

Background

Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk.

Methods

This single-arm phase 2 trial was done at three cancer centres (two hospitals and a cancer institute) in Boston (MA, USA). Eligible patients were aged at least 18 years and had transplant-eligible newly diagnosed multiple myeloma and an ECOG performance status of 2 or less. Patients received four 28-day cycles of Isa-KRd, including isatuximab 10 mg/kg intravenously weekly for 8 weeks, then every other week for 16 weeks, and every 4 weeks thereafter; carfilzomib 56 mg/m2 intravenously on days 1, 8, and 15 (20 mg/m2 for cycle 1 day 1); lenalidomide 25 mg orally on days 1–21; and dexamethasone 20 mg orally the day of and day after all doses of carfilzomib and isatuximab. Consolidation involved either upfront haematopoietic stem-cell transplantation (HSCT) with two additional cycles or deferred HSCT with four additional cycles of treatment. The primary endpoint was complete response after four cycles of treatment. Analyses were by intention-to-treat. All patients who received one dose of study drug were included in the safety analyses. This study was registered at ClinicalTrials.gov, NCT04430894, and has completed enrolment.

Findings

Between July 31, 2020 and Jan 31, 2022, 50 patients were enrolled. Median age was 59 years (range 40–70), 54% (27 of 50 patients) were male, and 44 (88%) were White. 46% (23 of 50) of patients had high-risk cytogenetics. Median follow-up was 26 months (IQR 20·7–30·1). 32% (16 of 50 patients) achieved a complete response after four cycles. The overall response rate (ORR) was 90% (45 patients) and 78% (39 patients) achieved a very good partial response (VGPR) or better. After completion of consolidation, 58% (29 patients) achieved a complete response; the ORR was 90% (45 patients) and 86% (43 patients) achieved a VGPR or better. The most common grade 3 or 4 side-effects (≥two patients) included neutropenia (13 [26%] of 50 patients), elevated alanine aminotransferase (six [12%] patients), fatigue (three [6%] patients), thrombocytopenia (three [6%] patients), acute kidney injury (two [4%] patients), anaemia (two [4%] patients), and febrile neutropenia (two [4%] patients). Grade 1–2 infusion-related reactions were seen in 20% (ten patients), with none grade 3. Grade 1–2 hypertension was seen in 14% (seven patients) with one grade 3 (one [2%] patient). There were two deaths assessed as unrelated to treatment.

Interpretation

Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting.

Funding

Amgen, Sanofi, and Adaptive.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杨烨华发布了新的文献求助10
1秒前
4秒前
阿翼完成签到 ,获得积分10
5秒前
5秒前
科研小民工应助南瓜豚采纳,获得40
6秒前
罗是一完成签到,获得积分10
6秒前
井水饮处完成签到,获得积分10
8秒前
尊敬西装发布了新的文献求助10
9秒前
胖肉肉发布了新的文献求助10
9秒前
杨烨华完成签到,获得积分20
9秒前
10秒前
今后应助111采纳,获得30
10秒前
10秒前
moonlin完成签到 ,获得积分10
11秒前
11秒前
Cker完成签到,获得积分10
11秒前
13秒前
彭于晏应助胖肉肉采纳,获得10
13秒前
Obliviate完成签到,获得积分10
14秒前
学术搭子完成签到,获得积分10
14秒前
慢慢子完成签到,获得积分10
14秒前
芳蔼发布了新的文献求助10
14秒前
鹏笑完成签到,获得积分10
15秒前
科研通AI2S应助乐观的非笑采纳,获得20
15秒前
悦耳问筠完成签到 ,获得积分10
16秒前
betty2009发布了新的文献求助30
16秒前
英勇含烟发布了新的文献求助10
17秒前
鑫儿发布了新的文献求助10
17秒前
迪鸣完成签到,获得积分10
17秒前
pattrick发布了新的文献求助10
18秒前
sushx完成签到,获得积分10
18秒前
顺利小鸭子完成签到,获得积分10
18秒前
酷波er应助成就的白羊采纳,获得10
19秒前
20秒前
研友_8RlXEn完成签到,获得积分10
21秒前
DC-liqingtian发布了新的文献求助10
22秒前
23秒前
花生完成签到 ,获得积分10
23秒前
欣慰的星月完成签到,获得积分10
23秒前
fff完成签到,获得积分10
24秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
Unusual formation of 4-diazo-3-nitriminopyrazoles upon acid nitration of pyrazolo[3,4-d][1,2,3]triazoles 500
岡本唐貴自伝的回想画集 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3671619
求助须知:如何正确求助?哪些是违规求助? 3228325
关于积分的说明 9779523
捐赠科研通 2938636
什么是DOI,文献DOI怎么找? 1610158
邀请新用户注册赠送积分活动 760547
科研通“疑难数据库(出版商)”最低求助积分说明 736093